Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measure Up 1: Upadacitinib in Moderate to Severe Atopic Dermatitis
NCT03569293Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Aug 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03569293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569293.